Composition and method for treating acute respiratory tract infections

Abstract

A composition consists of an effective amount of a synthetic neutral fucosylated human milk oligosaccharide (“HMO”), an effective amount of a synthetic neutral non-fucosylated HMO, and one or more excipients acceptable for enteral administration to a non-infant human. In some embodiments, the synthetic neutral fucosylated HMO is 2′-fucosyllactose and the synthetic neutral non-fucosylated HMO is selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”). In certain embodiments, the mass ratio of 2′-FL to the selected LNnT or LNT is about 1.5 to about 4.5. In one embodiment, the synthetic neutral non-fucosylated HMO is lacto-N-neotetraose (“LNnT”). In certain embodiments, the one or more excipients acceptable for enteral administration to a human are selected from diluents, antioxidants, lubricants, colorants, binders, disintegrants, and combinations thereof. In various embodiments, the one or more excipients are effective to form a galenic unit dosage form selected from a capsule, a tablet, and a sachet.

What is claimed is: 
     
         1 . A composition consisting of:
 an effective amount of a synthetic neutral fucosylated human milk oligosaccharide (“HMO”) consisting of 2′-fucosyllactose (“2′-FL”);   an effective amount of at least one synthetic neutral non-fucosylated HMO selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”); and   one or more excipients acceptable for enteral administration to a human.   
     
     
         2 . (canceled) 
     
     
         3 . The composition of  claim 1 , wherein the mass ratio in the composition of 2′-FL to the at least one synthetic neutral non-fucosylated HMO is about 1.5 to about 4.5. 
     
     
         4 . The composition of  claim 1 , wherein the synthetic neutral non-fucosylated HMO consists of lacto-N-neotetraose (“LNnT”). 
     
     
         5 . The composition of  claim 1 , wherein the one or more excipients acceptable for enteral administration to the human are selected from diluents, antioxidants, lubricants, colorants, binders, disintegrants, and combinations thereof. 
     
     
         6 . The composition of  claim 1 , wherein the one or more excipients are effective to form a galenic unit dosage form selected from a capsule, a tablet, and a sachet. 
     
     
         7 . A composition consisting essentially of:
 an effective amount of synthetic 2′-fucosyllactose (“2′-FL”) and at least one synthetic neutral human milk oligosaccharide (“HMO”) selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”).   
     
     
         8 . The composition of  claim 7 , wherein the mass ratio in the composition of 2′-FL to the at least one synthetic neutral non-fucosylated HMO is about 1.5 to about 4.5. 
     
     
         9 . The composition of  claim 7 , wherein the at least one synthetic neutral non-fucosylated HMO is lacto-N-neotetraose (“LNnT”). 
     
     
         10 . A composition consisting of:
 an effective amount of synthetic 2′-fucosyllactose (“2′-FL”) and at least one synthetic neutral human milk oligosaccharide (“HMO”) selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”).   
     
     
         11 . The composition of  claim 10 , wherein the mass ratio in the composition of 2′-FL to the at least one synthetic neutral non-fucosylated HMO is about 1.5 to about 4.5. 
     
     
         12 . The composition of  claim 11 , wherein the at least one synthetic neutral non-fucosylated HMO is lacto-N-neotetraose (“LNnT”).